Molecular Testing in Breast Cancer Current Status and Future Directions

被引：19

作者：

Sun, Lulu ^{[1
]}

Wu, Ariel ^{[1
]}

Bean, Gregory R. ^{[2
]}

Hagemann, Ian S. ^{[1
]}

Lin, Chieh-Yu ^{[1
]}

机构：

[1] Washington Univ, Dept Pathol & Immunol, Sch Med, St Louis, MO USA

[2] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA USA

来源：

JOURNAL OF MOLECULAR DIAGNOSTICS | 2021年 / 23卷 / 11期

关键词：

LATE DISTANT RECURRENCE; ENDOCRINE THERAPY; ONCOTYPE DX; PAM50; RISK; POSTMENOPAUSAL WOMEN; TREATMENT DECISIONS; 70-GENE SIGNATURE; AMERICAN SOCIETY; EXPRESSION ASSAY; GENE-EXPRESSION;

D O I：

10.1016/j.jmoldx.2021.07.026

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Molecular testing in breast cancer is a rapidly developing field that is becoming increasingly integral to patient care. This article provides an overview of currently available molecular assays and testing modalities that have prognostic, predictive, and therapeutic value. These include multigene assays for invasive breast cancer (Oncotype DX, MammaPrint, Prosigna, and Breast Cancer Index) and ductal carcinoma in situ (Oncotype DX DCIS and DCISionRT) and companion tests to detect PIK3CA mutations and NTRK fusions. The various assays related to immune checkpoint inhibitors, consisting of immunohistochemistry with antieprogrammed death-ligand 1 antibodies SP142 and 22C3 and detection of microsatellite instability, mismatch repair deficiency, and tumor mutational burden are also discussed. Finally, the practical utility and hopeful promise of next-generation sequencing panels and circulating tumor (cellfree) DNA assays are evaluated. This review should serve as a useful and practical reference for practicing pathologists, molecular pathologists, clinicians, and researchers.

引用

页码：1422 / 1432

页数：11

共 74 条

[1]

Abe O., 2010, Journal of the National Cancer Institute Monographs, P162, DOI 10.1093/jncimonographs/lgq039

[2] Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial [J].

Albain, Kathy S. ;

Barlow, William E. ;

Shak, Steven ;

Hortobagyi, Gabriel N. ;

Livingston, Robert B. ;

Yeh, I-Tien ;

Ravdin, Peter ;

Bugarini, Roberto ;

Boehner, Frederick L. ;

Davidson, Nancy E. ;

Sledge, George W. ;

Winer, Eric P. ;

Hudis, Clifford ;

Ingle, James N. ;

Perez, Edith A. ;

Pritchard, Kathleen I. ;

Shepherd, Lois ;

Gralow, Julie R. ;

Yoshizawa, Carl ;

Allred, D. Craig ;

Osborne, C. Kent ;

Hayes, Daniel F. .

LANCET ONCOLOGY, 2010, 11 (01) :55-65

[3] Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update [J].

Allison, Kimberly H. ;

Hammond, M. Elizabeth H. ;

Dowsett, Mitchell ;

McKernin, Shannon E. ;

Carey, Lisa A. ;

Fitzgibbons, Patrick L. ;

Hayes, Daniel F. ;

Lakhani, Sunil R. ;

Chavez-MacGregor, Mariana ;

Perlmutter, Jane ;

Perou, Charles M. ;

Regan, Meredith M. ;

Rimm, David L. ;

Symmans, W. Fraser ;

Torlakovic, Emina E. ;

Varella, Leticia ;

Viale, Giuseppe ;

Weisberg, Tracey F. ;

McShane, Lisa M. ;

Wolff, Antonio C. .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (12) :1346-+

[4]

Amin MB., 2017, AJCC Cancer Staging Manual, Ved 8

[5] Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer [J].

Andre, Fabrice ;

Ciruelos, Eva ;

Rubovszky, Gabor ;

Campone, Mario ;

Loibl, Sibylle ;

Rugo, Hope S. ;

Iwata, Hiroji ;

Conte, Pierfranco ;

Mayer, Ingrid A. ;

Kaufman, Bella ;

Yamashita, Toshinari ;

Lu, Yen-Shen ;

Inoue, Kenichi ;

Takahashi, Masato ;

Papai, Zsuzsanna ;

Longin, Anne-Sophie ;

Mills, David ;

Wilke, Celine ;

Hirawat, Samit ;

Juric, Dejan .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (20) :1929-1940

[6] Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial [J].

Bartlett, J. M. S. ;

Sgroi, D. C. ;

Treuner, K. ;

Zhang, Y. ;

Ahmed, I ;

Piper, T. ;

Salunga, R. ;

Brachtel, E. F. ;

Pirrie, S. J. ;

Schnabel, C. A. ;

Rea, D. W. .

ANNALS OF ONCOLOGY, 2019, 30 (11) :1776-1783

[7] Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer [J].

Bose, Ron ;

Kavuri, Shyam M. ;

Searleman, Adam C. ;

Shen, Wei ;

Shen, Dong ;

Koboldt, Daniel C. ;

Monsey, John ;

Goel, Nicholas ;

Aronson, Adam B. ;

Li, Shunqiang ;

Ma, Cynthia X. ;

Ding, Li ;

Mardis, Elaine R. ;

Ellis, Matthew J. .

CANCER DISCOVERY, 2013, 3 (02) :224-237

[8] A Biological Signature for Breast Ductal Carcinoma In Situ to Predict Radiotherapy Benefit and Assess Recurrence Risk [J].

Bremer, Troy ;

Whitworth, Pat W. ;

Patel, Rakesh ;

Savala, Jess ;

Barry, Todd ;

Lyle, Stephen ;

Leesman, Glen ;

Linke, Steven P. ;

Jirstrom, Karin ;

Zhou, Wenjing ;

Amini, Rose-Marie ;

Warnberg, Fredrik .

CLINICAL CANCER RESEARCH, 2018, 24 (23) :5895-5901

[9] Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time? [J].

Buono, Giuseppe ;

Gerratana, Lorenzo ;

Bulfoni, Michela ;

Provinciali, Nicoletta ;

Basile, Debora ;

Giuliano, Mario ;

Corvaja, Carla ;

Arpino, Grazia ;

Del Mastro, Lucia ;

De Placido, Sabino ;

De Laurentiis, Michele ;

Cristofanilli, Massimo ;

Puglisi, Fabio .

CANCER TREATMENT REVIEWS, 2019, 73 :73-83

[10] 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer [J].

Cardoso, F. ;

van't Veer, L. J. ;

Bogaerts, J. ;

Slaets, L. ;

Viale, G. ;

Delaloge, S. ;

Pierga, J. -Y. ;

Brain, E. ;

Causeret, S. ;

DeLorenzi, M. ;

Glas, A. M. ;

Golfinopoulos, V. ;

Goulioti, T. ;

Knox, S. ;

Matos, E. ;

Meulemans, B. ;

Neijenhuis, P. A. ;

Nitz, U. ;

Passalacqua, R. ;

Ravdin, P. ;

Rubio, I. T. ;

Saghatchian, M. ;

Smilde, T. J. ;

Sotiriou, C. ;

Stork, L. ;

Straehle, C. ;

Thomas, G. ;

Thompson, A. M. ;

van der Hoeven, J. M. ;

Vuylsteke, P. ;

Bernards, R. ;

Tryfonidis, K. ;

Rutgers, E. ;

Piccart, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (08) :717-729

← 1 2 3 4 5 6 7 8 →